Table 2.
Correlation between TAZ expression and clinicopathological parameters in ESCC.
| Han | P value | Kazakh | P value | Uygur | P value | Total | P value | |||||
| Clinicopathological parameters | TAZ | TAZ | TAZ | TAZ | ||||||||
| Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative | |||||
| Gender | ||||||||||||
| Male | 38 (64.4%) | 14 (87.5%) | .125 | 45 (61.6%) | 20 (62.5%) | .934 | 65 (67.7%) | 7 (77.8%) | .716 | 148 (64.9%) | 41 (71.9%) | .316 |
| Female | 21 (35.6%) | 2 (12.5%) | 28 (38.4%) | 12 (37.5%) | 31 (32.3%) | 2 (22.2%) | 80 (35.1%) | 16 (28.1%) | ||||
| Age | ||||||||||||
| <60 | 11 (18.6%) | 3 (18.75%) | 1 | 28 (38.4%) | 16 (50%) | .266 | 54 (56.25%) | 6 (66.7%) | .729 | 93 (40.8%) | 25 (43.9%) | .674 |
| ≥60 | 48 (81.4%) | 13 (81.25%) | 45 (61.6%) | 16 (50%) | 42 (43.75%) | 3 (33.3%) | 135 (59.2%) | 32 (56.1%) | ||||
| Tumor size | ||||||||||||
| <3 cm | 16 (27.1%) | 5 (31.25%) | .76 | 28 (38.4%) | 5 (15.6%) | .021 | 33 (34.4%) | 1 (11.1%) | .266 | 77 (33.8%) | 11 (19.3%) | .034 |
| ≥3 cm | 43 (72.9%) | 11 (68.75%) | 45 (61.6%) | 27 (84.4%) | 63 (65.6%) | 8 (88.9%) | 151 (66.2%) | 46 (80.7%) | ||||
| Degree of differentiation | ||||||||||||
| Poorly differentiated | 3 (5.1%) | 2 (12.5%) | .371 | 4 (5.5%) | 12 (37.5%) | 0 | 9 (9.4%) | 1 (11.1%) | 1 | 16 (7.0%) | 15 (26.4%) | .000 |
| Moderately differentiated | 38 (64.4%) | 11 (68.75%) | 41 (56.2%) | 4 (12.5%) | 66 (68.7%) | 6 (66.7%) | 145 (63.6%) | 21 (36.8%) | ||||
| Well differentiated | 18 (30.5%) | 3 (18.75%) | 28 (38.3%) | 16 (50%) | 21 (21.9%) | 2 (22.2%) | 67 (29.4%) | 21 (36.8%) | ||||
| Depth of invasion | ||||||||||||
| Mucosa | 7 (11.9%) | 0 (0%) | .348 | 4 (5.5%) | 0 (0%) | .029 | 0 (0%) | 1 (11.1%) | .015 | 11 (4.8%) | 1 (1.8%) | .029 |
| Muscularis | 25 (42.4%) | 8 (50%) | 29 (39.7%) | 21 (65.6%) | 42 (43.75%) | 6 (66.7%) | 96 (42.1%) | 35 (61.4%) | ||||
| Full-thickness | 27 (45.7%) | 8 (50%) | 40 (54.8%) | 11 (34.4%) | 54 (56.25%) | 2 (22.2%) | 121 (53.1%) | 21 (36.8%) | ||||
| TNM stage | ||||||||||||
| IA + B | 14 (24.1%) | 5 (31.25%) | .88 | 16 (21.9%) | 4 (12.5%) | .027 | 26 (27.1%) | 7 (77.8%) | .011 | 56 (17.4%) | 16 (27.6%) | .083 |
| IIA + B | 27 (46.6%) | 6 (37.5%) | 52 (71.2%) | 20 (62.5%) | 61 (63.5%) | 1 (11.1%) | 140 (67.6%) | 27 (46.5%) | ||||
| IIIA + B | 5 (8.6%) | 1 (6.25%) | 5 (6.9%) | 8 (25%) | 7 (6.25%) | 1 (11.1%) | 17 (7.7%) | 10 (19.0%) | ||||
| IVA + B | 12 (20.7%) | 4 (25%) | 0 (0%) | 0 (0%) | 3 (3.1%) | 0 (0%) | 15 (7.3%) | 4 (6.9%) | ||||
| Lymph node metastasis | ||||||||||||
| Yes | 21 (35.6%) | 7 (43.75%) | .55 | 24 (28.9%) | 2 (6.25%) | .009 | 37 (38.5%) | 0 (0%) | .025 | 82 (34.5%) | 9 (15.8%) | .006 |
| No | 38 (64.4%) | 9 (56.25%) | 59 (71.1%) | 30 (93.75%) | 59 (61.5%) | 9 (100%) | 156 (65.5%) | 48 (84.2%) | ||||
| Vascular invasion | ||||||||||||
| Yes | 9 (15.2%) | 1 (6.25%) | .679 | 8 (11%) | 6 (18.75%) | .351 | 20 (21%) | 1 (11.1%) | .683 | 37 (16.3%) | 8 (14%) | .676 |
| No | 50 (84.8%) | 15 (93.75%) | 65 (89%) | 26 (81.25%) | 75 (78.9%) | 8 (88.9%) | 190 (83.7%) | 49 (86%) | ||||
| Nerve invasion | ||||||||||||
| Yes | 7 (11.9%) | 1 (6.25%) | 1 | 20 (27.4%) | 8 (25%) | 1 | 18 (18.75%) | 0 (0%) | .352 | 45 (19.7%) | 9 (15.8%) | .496 |
| No | 52 (88.1%) | 15 (93.75%) | 53 (72.6%) | 24 (75%) | 78 (81.25%) | 9 (100%) | 183 (80.3%) | 48 (84.2%) | ||||
| Ethnic | ||||||||||||
| Han | 59 (25.9%) | 16 (28.1%) | ||||||||||
| Kazakh | 73 (32%) | 32 (56.1%) | <.001 | |||||||||
| Uygur | 96 (42.1%) | 9 (15.8%) | ||||||||||
There were 21 missing data due to the loss of connection in some patients during the follow-up.
ESCC = esophageal squamous cell carcinoma, TAZ = transcriptional co-activator with PDZ binding motif.